Mindray Medical's MR 4Q results were largely in line with its preliminary announcement in January. The first-time 2011 net income guidance of north of 10% may disappoint some, but reasonable given the investment in SG&A and R&D and was in line with Oppenheimer's forecast. Separately, MR agreed to acquire a controlling stake of Shenzhen Shenke, a worldwide supplier of syringe pumps, infusion pumps, and infusion care management systems.
Oppenheimer believes innovation remains key to MR's sustainable growth.
Internal development and technology acquisition will be viewed positively to aid
MR's expansion into the high-end market. MR's strong balance sheet will help.
Things to listen for on the conference call today include: recovery of China sales, especially on the non-tender side; details of the Shenke acquisition; future acquisitions to help MR expand into high-end markets; and cost control\
Oppenheimer has a Perform rating on Mindray Medical
MR closed Monday at $27.08
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in